ACADIA Pharmaceuticals Inc. $ACAD Shares Acquired by Yousif Capital Management LLC

Yousif Capital Management LLC boosted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,773 shares of the biopharmaceutical company’s stock after purchasing an additional 790 shares during the quarter. Yousif Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $1,009,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ACAD. American Century Companies Inc. raised its stake in ACADIA Pharmaceuticals by 1,055.8% in the 1st quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company’s stock valued at $27,120,000 after purchasing an additional 1,491,484 shares during the last quarter. Nuveen LLC acquired a new position in ACADIA Pharmaceuticals in the 1st quarter valued at $21,630,000. Vanguard Group Inc. raised its stake in ACADIA Pharmaceuticals by 9.0% in the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock valued at $252,526,000 after purchasing an additional 1,255,594 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in ACADIA Pharmaceuticals by 73.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,977,432 shares of the biopharmaceutical company’s stock valued at $32,845,000 after purchasing an additional 838,728 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in ACADIA Pharmaceuticals by 425.2% in the 1st quarter. Principal Financial Group Inc. now owns 754,748 shares of the biopharmaceutical company’s stock valued at $12,536,000 after purchasing an additional 611,054 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Oppenheimer reissued a “market perform” rating and issued a $22.00 price objective (up from $19.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. The Goldman Sachs Group raised their target price on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a “sell” rating in a research note on Thursday, August 7th. Citigroup assumed coverage on ACADIA Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $33.00 target price for the company. JPMorgan Chase & Co. cut their target price on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research note on Monday, September 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $29.33.

ACADIA Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:ACAD opened at $21.27 on Wednesday. The business has a 50-day moving average price of $23.44 and a 200 day moving average price of $21.20. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 7.36 and a beta of 0.75. ACADIA Pharmaceuticals Inc. has a 12-month low of $13.40 and a 12-month high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $264.57 million during the quarter, compared to the consensus estimate of $263.07 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $0.20 EPS. As a group, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Mark C. Schneyer sold 3,498 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $23.65, for a total transaction of $82,727.70. Following the completion of the sale, the executive vice president directly owned 43,447 shares of the company’s stock, valued at approximately $1,027,521.55. This trade represents a 7.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Elizabeth A. Garofalo sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total value of $41,568.00. Following the transaction, the director owned 25,382 shares of the company’s stock, valued at $659,424.36. This trade represents a 5.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,098 shares of company stock valued at $678,256 over the last three months. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.